Wearable ultrasound sensor revolutionizes continuous blood pressure monitoring

Researchers validated a novel wearable ultrasound blood pressure (BP) sensor, confirming its accuracy and safety across diverse clinical settings.

Pα+ Psychedelic Bulletin #175: atai Sells a Third of Compass Stake; Lykos’ Unproven Psychotherapy Hampered Studies, Claim Academics; Picking Placebos – Psychedelic Alpha

In this Issue atai Sells a Third of Compass Stake to Raise Cash for In-House Programs Lykos’ Unproven Psychotherapy Hampered Studies, Claim Authors of New

October 4, 2024

KT-253 by Kymera Therapeutics for Myeloproliferative Disorders: Likelihood of Approval

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes

November 5, 2023

SpringWorks stalled in pre-launch mode for brand communications after FDA decision delay

SpringWorks Therapeutics was cruising along with its pre-launch marketing plans for its rare desmoid tumor drug candidate nirogacestat. Its FDA decision date was set for

July 7, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.